Preclinical data presented at the American Epilepsy Society (AES) Annual Meeting provide additional evidence supporting Glyph’s ability to be applied across a wide range of molecules Application of ...
GlyphAgo is designed to overcome a key limitation of agomelatine by shifting absorption toward the intestinal lymphatics, avoiding first-pass liver metabolism, and increasing systemic exposure of the ...
Buccal drug delivery systems represent an innovative strategy for the administration of therapeutic agents via the oral mucosa. This approach bypasses the hepatic first‐pass metabolism, thereby ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results